Neuroendocrine responses to inhibitors of steroid biosynthesis in patients with major depression resistant to antidepressant therapy

Canadian Journal of Psychiatry

Volumn 43, Issue 3, 1998, Pages 279-286

  Murphy, Beverley E Pearson ^a,b   Ghadirian, A Missagh ^a   Dhar, Veena ^a,c  

^a MCGILL UNIVERSITY   (Canada)

^b MONTREAL GENERAL HOSPITAL   (Canada)

^c Private Practitioner

Author keywords

Adrenocorticotropin; Aminoglutethimide; Antiglucocorticoid; Cortisol; Dehydroepiandrosterone; Depression; Ketoconaz ole; Metyrapone

Indexed keywords

AMINOGLUTETHIMIDE; ANTIDEPRESSANT AGENT; CORTICOTROPIN; DEXAMETHASONE; GLUCOCORTICOID ANTAGONIST; HYDROCORTISONE; KETOCONAZOLE; METYRAPONE; PRASTERONE SULFATE; STEROID HORMONE; TESTOSTERONE;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CORTICOSTEROID METABOLISM; DEPRESSION; FATIGUE; FEMALE; HAMILTON SCALE; HEADACHE; HORMONE RELEASE; HUMAN; MALE; NAUSEA; NEUROENDOCRINE SYSTEM; RASH; STEROIDOGENESIS; VERTIGO;

EID: 0031784538     PISSN: 07067437     EISSN: None     Source Type: Journal    
DOI: 10.1177/070674379804300307     Document Type: Article

References (28)

1. Murphy BEP. Steroids and depression. Journal of Steroid Biochemistry and Molecular Biology 1991;38:537-58.
2. Starkman MN. The HPA axis and psychopathology: Cushing's syndrome. Psychiatric Annals 1993;23:691-701.
3. Reus VI, Woikowitz WM. Behavioral side effects of corticosteroid therapy. Psychiatric Annals 1993;23:703-8.
4. Arana GW, Santos AB, Laraia MT, McLeod-Bryant S, Beale MD, Rames LJ, and others. Dexamethasone for the treatment of depression: a randomized, placebo-controlled, double-blind trial. Am J Psychiatry 1995;152:265-7.
5. Murphy BEP.Treatment of major depression with steroid suppressive therapy. J Steroid Biochem Mol Biol 1991;39:239-44.
6. Murphy BEP, Dhar V, Ghadirian AM, Chouinard G, Keller R. Response to steroid suppression in major depression resistant to antidepressant therapy. J Clin Psychopharmacol 1991;11:121-6.
7. Ghadirian AM, Engelsmann F, Dhar V, Filipini D, Keller R, Chouinard G, and others. The psychotropic effects of inhibitors of steroid biosynthesis in depressed patients refractory to treatment. Journal of Biological Psychiatry 1995;37:369-75.
8. Wolkowitz OM, Reus VI, Manfredi F, Ingbar J, Brizendine L, Weingartner H. Ketoconazole administration in hypercortisolemic depression. Am J Psychiatry 1993;150:810-2.
9. O'Dwyer A-M, Lightman SL, Marks MKN, Checkley SA. Treatment of major depression with metyrapone and hydrocortisone. J Affect Disord 1995;33:123-8.
10. Anand A, Malison R, McDougle CJ, Price LH. Antiglucocorticoid treatment of refractory depression with ketoconazole: a case report. Biol Psychiatry 1995;37:338-40.
11. Thakore JH, Dinan T. Cortisol synthesis inhibition: a new treatment strategy for the clinical and endocrine manifestations of depression. Biol Psychiatry 1995;37:364-8.
12. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 3rd ed. Revised. Washington (DC): American Psychiatric Association; 1987.
13. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960;23:55-62.
14. Santen RJ, Wells SA, Runic S, Gupta C, Kendall J, Rudy ED, and others. Adrenal suppression with aminoglutethimide: part I. Differential metabolism as a rationale for use of hydrocortisone. J Clin Endocrinol Metab 1977;45:469-79.
15. Santen RJ, Wells SA. The use of aminoglutethimide in the treatment of patients with metastalic carcinoma of the breast. Cancer 1980;46:1066-74.
16. American Psychiatric Association. Practice guideline for major depressive disorder in adults. Am J Psychiatry 1993;150(Suppl):1S-26S.
17. Osran H, Reist C, Chen C-C, Lifrak ET, Chicz-Demet A, Parker LN. Adrenal androgens and cortisol in major depression. Am J Psychiatry 1993;150:806-9.
18. Reus VI, Wolkowitz OM, Roberts E, Chan T, Turetsky N, Manfredi F, and others. Dehydroepiandrosterone (DHEA) and memory in depressed patients. Neuropsychopharmacology 1993;9(Suppl):66S.
19. Starkman MN, Schteingan DE, Schork MA. Discordant changes in plasma ACTH and -lipotropin/-endorphin levels in Cushing's disease patients with depression. Psychoneuroendocrinology 1992;17:619-26.
20. Goverde JM, Martens GH, Pesman GH, Smals GH. Multiple forms of bioactive and immunoreactive adrenocorticotropin in human pituitary and blood of patients with Nelson's syndrome. J Clin Endocrinol Metab 1993;77:443-7.
21. Gibson S, Crosby SR, Stewart MF, Jennings AM, McCall E, White A. Differential release of proopiomelanocortin-derived peptides from the human pituitary: evidence from a panel of two-site immunoradiometric assays. J Clin Endocrinol Metab 1994;78:835-41.
22. Trachtenberg J, Zadra J. Steroid synthesis inhibition by ketoconazole: sites of action. Clin Invest Med 1988;11:1-5.
23. Martikainen H, Heikkinen J, Ruokonen A, Kauppila A. Hormonal and clinical effects of ketoconazole in hirsute women. J Clin Endocrinol Metab 1988;66:987-91.
24. Verhelst JA, Trainer PJ, Howlett TA, Perry L, Rees LH, Grossman AB, and others. Short and long-term responses to metyrapone in the medical management of 91 patients with Cushing's syndrome. J Clin Endocrinol Metab 1991;35: 169-78.
25. Pont A, Graybill JR, Craven PC, Galgiani JN, Dismukes WE, Reitz RE, and others. High-dose ketoconazole therapy and adrenal and testicular function in humans. Arch Intern Med 1984;144:2150-3.
26. Murphy BEP, Filipini D, Ghadirian AM. Possible use of glucocorticoid antagonists in the treatment of major depression: preliminary results using RU 486. J Psychiatry Neurosci 1993;18:209-13.
27. Murphy BEP. Antigiucocorticoid therapies in major depression: a review, Psychoneuroendocrinoiogy 1997;22(1 Suppl);125S-132S.
28. Ravaris CL, Sateia MJ, Beroza W, Noorday DL, Brinck-Johnsen T. Effect of ketoconazole on a hypophysectomized, hypercortisolemic, psychotically depressed woman. Arch Gen Psychiatry 1988;45:966-7.